脂蛋白(α)的生理功能及其与冠心病的研究进展  

Physiological functions and research progress of lipoprotein( α) in coronary heart disease

作　　者：左瑞平[1] 张建军[1] 韩常宝[1] 

机构地区：[1]北京军区总医院二六三临床部心内科,北京101149

出　　处：《心脏杂志》2016年第2期244-247,共4页Chinese Heart Journal

摘　　要：载脂蛋白(a)〔apo(a)〕是一种具有高度基因多态性的糖蛋白。apo(a)在肝脏合成后与LDL上的apo(B100)具有高度亲和力,在肝细胞表面通过二硫键与之相连形成脂蛋白(α)〔Lp(α)〕。Lp(α)通过LDL受体途径及非LDL受体途径代谢。Lp(α)参与动脉粥样硬化的发生、发展,在止血、创伤愈合及血管发生中也发挥作用。Lp(α)是冠心病的独立危险因素。Lp(α)血浆水平主要由遗传因素决定,但可受疾病(如:肝脏及肾脏疾病)、激素(如:性腺激素、甲状腺激素)及药物(如:烟酸及其类似物)的轻度影响。本文对Lp(α)血浆浓度的种族差异、性别差异及药物影响进行了阐述。Apo（α） is a glycoprotein that underlies a large genetic polymorphism. Apo（a） is synthesized predominantly in the liver. After its synthesis, it binds with high affinity to the apoB binding site of LDL on the hepatocellular surface. Lipoprotein （α） [ Lp （α） ] is degraded via LDL-receptor metabolic pathway and non-LDL-receptor metabolic pathway. Lp （α） is an important agent in the development of atheroscle- rosis and has some physiological functions in hemostasis, wound healing and angiogenesis. Lp（α） is an independent risk marker for coronary heart disease. Lp （α） plasma concentration is highly determined by genetic factors. However, plasma concentrations of Lp （α） are also affected by different diseases （ e. g. , diseases of liver and kidney） , hormonal factors （ e. g. , sex steroids, thyroid hormones） as well as pharmaceuticals （e. g. , nicotinic acid derivatives）. This article focuses mainly on racial and sex differences of Lp （α） levels and influences of medication.

关 键 词：脂蛋白Α 生理功能 冠状动脉疾病 

分 类 号：R541.4[医药卫生—心血管疾病]